Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.47 |
| ▸ | MGLL | Q99685 | 2/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.39 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.39 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.39 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.39 |
| ▸ | LIPE | Q05469 | 1/20 | 0.39 |
| ▸ | CFTR | P13569 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2463852 | 1.00 | ENPP2 (0.47) | ENPP2MGLLTRPV1CYP2C19L3MBTL1 | |
| SCHEMBL319585 | 0.85 | ENPP2 (0.47) | ENPP2MGLLCYP2C19L3MBTL1RAB9A | |
| SCHEMBL29588618 | 0.85 | ENPP2 (0.47) | ENPP2MGLLCYP2C19L3MBTL1RAB9A | |
| SCHEMBL25368443 | 0.84 | MGLL (0.42) | MGLLCYP2C19L3MBTL1RAB9AKDM4E | |
| SCHEMBL29957898 | 0.83 | TRPV1 (0.52) | ENPP2TRPV1ALDH1A1HPGDHSD17B10 | |
| SCHEMBL12118475 | 0.83 | TRPV1 (0.52) | ENPP2TRPV1ALDH1A1HPGDHSD17B10 | |
| SCHEMBL29954769 | 0.82 | MGLL (0.41) | MGLLCYP2C19KDM4EUSP2ALDH1A1 | |
| SCHEMBL1042131 | 0.82 | KDM4E (0.39) | MGLLCYP2C19L3MBTL1RAB9AKDM4E | |
| SCHEMBL30994957 | 0.82 | KDM4E (0.39) | MGLLCYP2C19L3MBTL1RAB9AKDM4E | |
| SCHEMBL29953373 | 0.81 | CYP2C19 (0.51) | MGLLCYP2C19L3MBTL1KDM4EUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025215450-A1 | THIAZOLE COMPOUNDS AS SODIUM CHANNEL BLOCKERS | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2025-10-16 | — | — | WO | disclosed |
| CN-120152964-A | Triazinone derivatives as NLRP3 inhibitors | 豪夫迈·罗氏有限公司 | 2025-06-13 | — | — | CN | disclosed |
| EP-4562009-A1 | NOVEL COMPOUNDS | AC Immune SA (CH) | 2025-06-04 | — | — | EP | disclosed |
| EP-4554945-A1 | PYRROLOTRIAZINE AND IMIDAZOTRIAZINE DERIVATIVES AS MODULATORS OF THE NLRP3 INFLAMMASOME PATHWAY | AC Immune SA (CH) | 2025-05-21 | — | — | EP | disclosed |
| CN-119907802-A | Pyrrolotriazine and imidazotriazine derivatives as modulators of NLRP3 inflammatory small body pathways | AC免疫有限公司 | 2025-04-29 | — | — | CN | disclosed |
| CN-119894869-A | Substituted biaryl kadetoxin-like quinolones having enhanced antiparasitic activity | 俄勒冈健康与科学大学 | 2025-04-25 | — | — | CN | disclosed |
| EP-4536639-A1 | SUBSTITUTED BIARYL ENDOCHIN-LIKE QUINOLONES WITH ENHANCED ANTIPARASITIC ACTIVITY | Oregon Health & Science University (US) | 2025-04-16 | — | — | EP | disclosed |
| EP-4493556-A1 | NLRP3 MODULATORS | Zomagen Biosciences Ltd (US) | 2025-01-22 | — | — | EP | disclosed |
| CN-119301116-A | NLRP3 modulators | 祖玛珍生物科学有限公司 | 2025-01-10 | — | — | CN | disclosed |
| US-20250002470-A1 | NITROGEN-CONTAINING COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | ZHEJIANG AIXPLORER BIOTECH CO., LTD. (CN) | 2025-01-02 | — | — | US | disclosed |
| WO-2023239811-A1 | SUBSTITUTED BIARYL ENDOCHIN-LIKE QUINOLONES WITH ENHANCED ANTIPARASITIC ACTIVITY | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023178099-A1 | NLRP3 MODULATORS | ZOMAGEN BIOSCIENCES LTD (US) | 2023-09-21 | — | — | WO | disclosed |
| CN-110612289-B | Deuterated benzimidazole compound and medical application thereof | 住友制药株式会社 | 2023-06-30 | — | — | CN | disclosed |
| WO-2023109912-A1 | 3, 4-DIHYDROISOQUINOLIN-1 (2H) -ONES DERIVATIVES AS STING ANTAGONISTS AND THE USE THEREOF | BEIGENE, LTD. (KY) | 2023-06-22 | — | — | WO | disclosed |
| CN-116102535-A | Nitrogen-containing compound, preparation method and application thereof | 索智生物科技（浙江）有限公司 | 2023-05-12 | — | — | CN | disclosed |
| WO-2023066825-A1 | FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-04-27 | — | — | WO | disclosed |
| CN-107759522-B | Carboxylic acid derivative, preparation method thereof and application thereof in medicine | 浙江海正药业股份有限公司 | 2023-04-14 | — | — | CN | disclosed |
| WO-2023028536-A1 | 1,2,4-TRIAZINE DERIVATIVES USEFUL AS INHIBITORS OF NLRP3 | PTC THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| WO-2023028534-A1 | INHIBITORS OF NLRP3 | PTC THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250002470-A1 | NITROGEN-CONTAINING COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | NOD1, NLRP3, NLRP1 | ENPP2 3374/4885MGLL 1801/4885TRPV1 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.